Document:

exhibit1052.htm

    Exhibit 10.52

    The confidential portions
of this exhibit have been filed separately with the Securities and Exchange
Commission pursuant to a confidential treatment request in accordance with Rule
24b-2 of the Securities and Exchange Act of 1934, as amended.  REDACTED
PORTIONS OF THIS EXHIBIT ARE MARKED BY AN [##].

    Amendment
and Addendum to

     

    Consultant
Services and Confidentiality Agreement

     

    This
Amendment and Addendum to Consultant Services and Confidentiality Agreement
(the “Amendment”)
is entered into as of December 1, 2008 (the “Amendment
Date”) by and between, on the one hand, OMP,
Inc., a Delaware corporation (“OMP”);
and, on the other hand, José
Ramirez, an individual, and JR Chem
LLC, a Florida limited liability company (collectively, “JR”).  All
capitalized terms used but not otherwise defined herein shall have the meanings
assigned under the Consultant Services and Confidentiality Agreement between OMP
and JR dated as of July 18, 2005 (the “Original
Agreement” and, collectively with, and as amended by, this Amendment, the
“Agreement”).

     

    Whereas,
subject to the terms and conditions of the OriginalAgreement, and
effective as of July 18, 2005, JR granted to OMP, during the License Term,
an exclusive, royalty-bearing license, including the right to sublicense through
multiple tiers of sublicense, under the Licensed Technology, to develop, make,
have made, use, sell, have sold, offer for sale and import BiMineral Complex and
Products;

     

    Whereas,
OMP and JR wish to amend the terms and conditions applicable to the
license granted by JR to OMP with respect to the BiMineral Complex (defined
below) but only insofar as it applies to sales to Rohto (as defined below);
and

     

    Whereas,
OMP currently wishes to sub-license products set forth on Exhibit A
that contain the BiMineral Complex to Rohto Pharmaceutical Co. Ltd., a Japanese
corporation with principal offices located at 1-8-1, Tatsumi-nishi, Ikuno-ku,
Osaka 544-8666, Japan (“Rohto”).

     

    Now,
Therefore, in consideration of the foregoing recitals and the mutual
promises hereinafter set forth, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties agree
as follows:

     

    1. Additional
Defined Terms.

     

    (a)           “BiMineral Complex” shall mean
reacted active, copper zinc malonate.

     

    (b)           “Effective Date” shall mean
July 18, 2005.

     

    (c)           “Field” shall mean Skin
Healthcare, dermatology, aesthetic procedures, plastic surgery, and each other
use described in Exhibit B to the Original Agreement.

     

    (d)           “Licensed Patents” shall mean:
(a) the patents and patent applications listed in Schedule 1
to this Amendment; (b) any and all divisionals, continuations and
continuations-in-part of any of the foregoing patents and patent applications;
(c) any and all foreign patents and patent applications associated with any
of the foregoing patents and patent applications; (d) any and all patents
issued or issuing from any of the foregoing patent applications; and
(e) reissues, reexaminations, restorations (including supplemental
protection certificates) and extensions of any of the foregoing.

     

    

    
      
        
          
             

          

           

        

        
          1

          
            

          

        

        
           

        

      

    

    

    (e)           “Licensed Technology” shall
mean the Licensed Patents and all related know-how disclosed, or that may in the
future be disclosed, to OMP in connection with the Services or otherwise
pursuant to the Agreement.

     

    (f)           “License Term” shall mean the
period beginning on the Effective Date and, unless the license granted under
this Amendment is earlier terminated in accordance with Section 2(b) of
this Amendment, continuing until the expiration of all royalty payment
obligations hereunder.

     

    (g)           “Product” shall mean any
product in any form or formulation that contains or incorporates BiMineral
Complex.

     

    (h)           “Sales Revenues” shall mean
the amounts actually received by OMP from the sale of BiMineral Complex and/or
Product, as applicable, to Rohto.

     

    (i)           “Unit” shall mean a single
unit of a particular Product that is intended for sale to the end user or
consumer.

     

    (j)           “Valid Claim” shall mean a
claim contained in an issued and unexpired patent which has not been held
unenforceable, unpatentable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through abandonment, reissue, disclaimer or
otherwise.

     

    2. Payments.

     

    (a) Royalty.  In full
consideration of the license granted under this Amendment, OMP shall pay to JR
royalties based on Rohto annual Sales Revenues paid to OMP at the rates set
forth below:

     

    (i) [ 1* ] of
the first [ 2* ] Units of Product in any calendar year;

     

    (ii) [ 3*
] of  the [ 4* ] Unit (inclusive) of Product in any calendar
year ;

     

    (iii) [ 5*
]  of the [ 6* ] Unit (inclusive) of Product in any calendar year;
and

     

    (iv) [ 7*
]  of the [ 8* ]  of Product in any calendar year.

     

     (b)           Royalty
Term.  Royalties under Section 2(a) of this Amendment
shall be payable based on Rohto annual Sales Revenues until the expiration of
the last-to-expire Valid Claim of the Licensed Patents that claims the
manufacture, use or sale of a Product (or the BiMineral Complex contained in
such Product, as applicable) in Japan. For purposes of clarification, royalties
shall only be payable if there is at least one Valid Claim of the Licensed
Patents claiming the manufacture, use or sale of the applicable Product (or the
BiMineral Complex contained in such Product, as applicable) in
Japan.

     

    * Subject
to confidential treatment request

    
      
        
          
            

                                                                             
..

            

          

           

        

        
          2

          
            

          

        

        
           

        

      

    

    

    (c)           Payment;
Reports.  Royalties shall be calculated and reported for each
calendar quarter and shall be paid within [ 9* ] after the end of each calendar
quarter.  Each payment shall be accompanied by a report of Sales
Revenues in sufficient detail to permit confirmation of the accuracy of the
royalty payment made, including the number of Units of Product to which such
Sales Revenues are attributable, the royalties payable, and the exchange rates
used.  

     

    (d)           Exchange Rate; Manner and Place of
Payment.  All payments hereunder shall be payable in U.S.
dollars.  When conversion of payments from any foreign currency is
required, such conversion shall be at the exchange rate used by OMP throughout
its accounting system during the calendar quarter for which a payment is
due.  All payments owed under this Amendment shall be made by wire
transfer in immediately available funds to a bank and account designated in
writing by JR, unless otherwise specified in writing by JR.

     

    (e)           Income Tax
Withholding.  JR will pay any and all taxes levied on account
of any payments made to it under this Amendment.  If any taxes are
required to be withheld by OMP, OMP will (i) deduct such taxes from the
payment made to JR, (ii) timely pay the taxes to the proper taxing
authority, and (iii) send proof of payment to JR and certify its receipt by
the taxing authority as promptly as practicable following such
payment.

     

    (f)           Audits.  For so long
as royalty payments are due hereunder and for a period of three (3) years
thereafter, OMP shall keep records pertaining to Sales Revenues in sufficient
detail to permit JR to confirm the accuracy of the royalty payments due
hereunder.  JR shall have the right, exercisable no more than once
annually, to cause an independent, certified public accountant reasonably
acceptable to OMP to audit such records to confirm Sales Revenues and royalties
for a period covering not more than the preceding three (3)
years.  Such audits may be exercised during normal business hours upon
reasonable prior written notice to OMP.  Prompt adjustments shall be
made by the parties to reflect the results of such audit.  JR shall
bear the full cost of such audit unless such audit discloses an underpayment by
OMP of more than 10% of the royalties due under this Amendment, in which case,
OMP shall bear the full cost of such audit and shall promptly remit to JR the
amount of any underpayment.

     

    (g)           Sales Revenues from Other
Customers                                                                                     JR
understands and agrees that the royalty payments in this Agreement are solely
derived from OMP’s royalty payments received from Rohto.  If OMP
negotiates a sub-license agreement with another customer other than Rohto, the
terms of the Original Agreement shall apply unless JR and OMP negotiate in good
faith another amendment to satisfy that demand.

     

    3. Termination
of License. For the avoidance of doubt, the License Term shall be
independent, and shall survive expiration or termination, of the Original
Agreement.  Rights to terminate shall be as set forth in the Original
Agreement.

     

    4. Miscellaneous.  Except as specifically
amended by this Amendment, the terms and conditions of the Original Agreement
shall remain in full force and effect.  This Amendment may be executed
in counterparts, each of which shall be deemed an original document, and all of
which, together with this writing, shall be deemed one instrument.

     

    * Subject
to confidential treatment request

    
      
        
          
            

                                                                              
..

            

          

           

        

        
          3

          
            

          

        

        
           

        

      

    

    

    5. In Witness
Whereof, the parties hereto have executed this Amendment in duplicate
originals by their duly authorized officers or representatives.

     

    
      	
              OMP,
      Inc.

            	
              JR
      Chem LLC

            

    

     

    

     

    By:                                                                By:                                                                

     

    Name:                                                                           Name:

     

    Title:                                                                           Title:

     

    

     

    José
Ramirez

     

    

     

    

     

    

    
      
        
          
            

                                                                         
..

            

          

           

        

        
          4

          
            

          

        

        
           

        

      

    

    

    EXHIBIT
A

    BiMineral
Complex

    

    The
BiMineral Complex to be supplied by OMP to Rohto under this Agreement is the
reacted active, copper zinc malonate.  The BiMineral Complex is
prepared in two concentrates, one prepared for a cream-based formulation and one
prepared for a gel-based formulation.

    

    Cream-based concentrate
(Complex JR
23-14):

    Per the
current formulation used by JR, the Eye Cream uses approximately 0.375g per 15g
unit of Product.  The Eye Cream liquid 40X reacted copper zinc
malonate will be supplied in sanitary polyolefin drums.  Appropriate
MSDS and chemical analysis for Cu, Zn, pH and microbial quality will be supplied
with each lot of BiMineral Complex delivered to Rohto.

    

    The
Purchase Orders placed by Rohto shall be in multiples of 25kg (each 25kg is
sufficient quantity for producing approximately 66000 Eye Cream units per the
OMP formulation).  The price for the 40X concentrate custom made for
the Eye Cream is [ 10* ]/kg.

    

    Gel-based concentrate
(Complex JR
23-15):

    Per the
current formulation used by JR, the Eye Gel uses approximately 0.35g per 15g
unit of Product.  The gel base liquid is a 40X concentrate (due to the
manufacturing difference and pH adjustments required in the gel).  As
above, appropriate chemical analysis and MSDS will be provided.

    

    The
Purchase Orders placed with OMP directly by Rohto shall be in multiples of 25kg
(each 25kg is sufficient quantity for producing approximately 100,000 Eye Gel
units per the OMP formulation).  The price for the 40X concentrate
custom made for the Eye Gel is [ 11* ]  /kg.

    

     

    

    * Subject
to confidential treatment request

    

    
      
        
          
            

                                                                
..

            

          

           

        

        
          5

          
            

          

        

        
           

        

      

    

    

    Schedule
1

     

    Licensed
Patents

     

    
      	
              Reference:
      1169-36 CIP (Copper Zinc Malonate)

            
	
              Title:
      Chemical Compositions and Methods of Making Them

            
	
              Country

            	
              Application
      No.

            	
              Patent
      No.

            	
              Filing
      Date

            	
              Status

            
	
              JAPAN

            	
              [
      12* ]

            	 
      	
              [
      13* ] 

            	 
      
	 
      	
              [
      14* ] 

            	 
      	
              [
      15* ] 

            	 
      
	 
      	
              [
      16* ] 

            	 
      	
              [
      17* ] 

            	
              Laid
      Open No.

              P2007-204479A
      on 8/16/07

              Awaiting
      Office Action

            
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      

    

    

     

    
      	
              Reference:
      1169-37 PCT

            
	
              Title:
      Anti-aging Treatment Method using Copper Zinc
  Composition

            
	
              Country

            	
              Application
      No.

            	
              Patent
      No.

            	
              Filing
      Date

            	
              Status

            
	
              Need
      to specify Japan

            	
              [
      18* ] 

              [
      20* ] 

            	 
      	
              [
      19* ] 

              [
      21* ] 

            	
              Response
      to OA Due 12/16/08

            
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      

    

    

     

    
      	
              Reference:

            
	
              Title:

            
	
              Country

            	
              Application
      No.

            	
              Patent
      No.

            	
              Filing
      Date

            	
              Status

            
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      

    

    

    * Subject
to confidential treatment request

    

    6exhibit10-14.htm

     Exhibit
10.14

    

    Data
Domain, Inc.

    2421
Mission College Boulevard

     

    Santa
Clara, CA 95054

     

    September
22, 2008

    

    

    Nick
Bacica

    229
Monterey Street

    Santa
Cruz, CA 95060

    

    

    Dear Nick:

    

    

    Data
Domain, Inc. (the “Company”) is pleased to offer you employment on the following
terms:

     

    1. Position.  Your
initial title will be Vice President of Manufacturing. You will report to Pete
Rukavina, Senior Vice President, Operations. This is a full-time exempt
position. By signing this letter agreement, you confirm to the Company that you
have no contractual commitments or other legal obligations that would prohibit
you from performing your duties for the Company. This offer of employment is
contingent upon your execution of this offer of employment, your execution of
the employee Proprietary Information and Inventions Agreement, a clearance of
your background check and verification of your references.

     

    2. Base Salary.  The
Company will pay you a starting semi-monthly salary of $8,958 (an equivalent of
$215,000 annually), minus applicable state and federal withholdings, payable in
accordance with the Company’s standard payroll schedule.  This salary
will be subject to adjustment pursuant to the Company’s employee compensation
policies in effect from time to time. In addition, you will be eligible for an
incentive bonus for each fiscal quarter of the Company.  The bonus (if
any) will be awarded based on objective or subjective criteria established by
the Company’s Chief Executive Officer and approved by the Company’s Board of
Directors.  Your target annual bonus will be equal to $85,000.00
payable in quarterly increments of 25% of your annual target.  Any
bonus for the fiscal quarter in which your employment begins will be prorated,
based on the number of days you are employed by the Company during that fiscal
quarter.  The bonus for a fiscal quarter will be paid after the
Company’s books for that quarter have been closed and will be paid only if you
are employed by the Company at the time of payment.  The determination
of the Company’s Board of Directors with respect to your bonus will be final and
binding.

     

    3. Employee
Benefits.  As a regular employee of the Company, you will be
eligible to participate in a number of Company-sponsored benefits.  In
addition, you will be entitled to paid vacation in accordance with the Company’s
vacation policy. Note: Benefits are effective on
date of hire.

     

    4. Stock. Subject to the approval
of the Company’s Board of Directors, you will be granted an option to purchase
110,000 (one
hundred ten thousand) shares of the Company’s Common Stock.  The
exercise price per share will be equal to the fair market value per share on the
date the option is granted, and is subject to your continued employment on such
date. The option will be subject to the terms and conditions applicable to
options granted under the Company’s 2007 Stock Plan (the “Plan”), as described
in the Plan and the applicable Stock Option Agreement.  You will vest
in 25% of the option shares after 12 months of continuous service, and the
balance will vest in equal monthly installments over the next 36 months of
continuous service, as described in the applicable Stock Option
Agreement.

     

    In
the event of your Involuntary Termination (as defined below) of employment or
service within twelve (12) months following a Change in Control (as defined in
the Plan) and provided that you (a) sign a general release of claims (in a
form prescribed by the Company) of all known and unknown claims that you may
then have against the Company or persons affiliated with the Company and
(b) have returned all Company property, then you will vest in an additional
50% of any then unvested option shares and/or restricted shares, as applicable,
including, but not limited to the Option, as of the date of the Involuntary
Termination.

    5. Severance Pay. If the Company
terminates your employment for any reason other than Cause (as defined below) or
Permanent Disability (as defined below), then the Company will continue to pay
your base salary for a period of 3 months following the termination of your
employment. Your base salary will be paid at the rate in effect at the time of
the termination of your employment and in accordance with the Company’s standard
payroll procedures. If you elect to continue your health insurance coverage
under the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) following the
termination of your employment, then the Company will pay the same portion of
your monthly premium under COBRA as it pays for active employees until the
earliest of (a) the close of the 3-month period following the termination
of your employment, (b) the expiration of your continuation coverage under
COBRA or (c) the date you become eligible for substantially equivalent
health insurance coverage in connection with new employment.

     

    However, this Section 5 will not
apply unless you (a) sign a general release of claims (in a form prescribed
by the Company) of all known and unknown claims that you may then have against
the Company or persons affiliated with the Company and (b) have returned
all Company property. Moreover, the amount of the salary continuation payments
under this Section 5 will be reduced by the amount of any severance pay or
pay in lieu of notice that you receive from the Company under a federal or state
statute (including, without limitation, the WARN Act).

     

    For purposes of this Section 5,
termination of employment will be determined consistent with the rules relating
to “separation from service” as defined in Section 409A of the Internal Revenue
Code of 1986, as amended (“Section 409A”).Your severance payments will in no
event start before the earliest date permitted by
Section 409A(a)(2).  If the commencement of the severance
payments must be delayed, as determined by the Company, then the deferred
installments will be paid to you in a lump sum on the earliest practicable date
permitted by Section 409A(a)(2).

    

    6. Proprietary Information and
Inventions Agreement.  Like all Company employees, you will be
required, as a condition of your employment with the Company, to sign the
Company’s standard Proprietary Information and Inventions Agreement, a copy of
which is attached hereto as Exhibit A.

     

    7. Employment
Relationship.  Employment with the Company is for no specific
period of time.  Your employment with the Company will be “at will,”
meaning that either you or the Company may terminate your employment at any time
and for any reason, with or without cause.  Any contrary
representations that may have been made to you are superseded by this
offer.  This is the full and complete agreement between you and the
Company on this term.  Although your job duties, title, compensation
and benefits, as well as the Company’s personnel policies and procedures, may
change from time to time, the “at will” nature of your employment may only be
changed in an express written agreement signed by you and the Chief Executive
Officer of the Company.

     

    8. Outside
Activities.  While you render services to the Company, you
agree that you will not engage in any other employment, consulting or other
business activity without the prior written consent of the
Company.  While you render services to the Company, you also will not
assist any person or entity in competing with the Company, in preparing to
compete with the Company or in hiring any employees or consultants of the
Company.

     

    9. Withholding
Taxes.  All forms of compensation referred to in this letter
agreement are subject to reduction to reflect applicable withholding and payroll
taxes and other deductions required by law.

     

    10. Entire
Agreement.  This letter agreement supersedes and replaces any
prior agreements, representations or understandings, whether written, oral or
implied, between you and the Company.

     

    11. Additional Requirements. The
Immigration Reform Control Act requires employers to verify eligibility of all
personnel for employment in the United States.  The Eligibility
Verification Form (INS form I-9), will specify which documents you are required
to produce to establish such eligibility.  Please bring the required
documentation with you when you report for work on your first day.

     

    This
offer is contingent upon receipt of any export license or other approval that
may be required under United States export control laws and regulations. 
We are not obligated to apply for any export license or other approval that may
be required, nor can we guarantee that the United States Government will issue
an export license or other approval, in the event that we do file an
application.

     

    Nick,
we are very excited about the possibility that you will accept our offer to join
the Company.  You may indicate your agreement with these terms and
accept this offer by signing and dating both the enclosed duplicate original of
this letter agreement and the enclosed Proprietary Information and Inventions
Agreement and returning them to me.  This offer, if not accepted, will
expire at the close of business on September 25, 2008.

     

    If
you have any questions, please contact Michael Nguyen, Staffing Coordinator at
408-986-4110.

     

    
      	 
      	
              Very
      truly yours,

            
	 
      	
              Data
      Domain, Inc.

            
	 
      	
              /s/
      Shelly Begun

            
	 
      	
              By:  Shelly
      Begun

            
	 
      	
              Title:  Vice
      President, Human Resources

            

    

    

     

    
      	
              I
      have read and accept this employment offer:

            	 
      
	
              
                /s/
      Nick Bacica

              

            	 
      
	
              Signature
      of Nick Bacica

            	 
      
	 
      	 
      
	
              
                Dated:  9/23/08

              

            	 
      
	 
      	 
      
	
              
                Start
      Date: 9/29/08

              

            	 
      
	
              Attachment

            	 
      
	
              Exhibit
      A: Proprietary Information and Inventions Agreement

            	 
      
	 
      	 
      
	
              Please
      initial all pages and sign the last page.

            	 
      
	
              Fax
      all pages to: Attention Michael Nguyen

            	 
      
	
              Confidential
      fax line: 408-986-4294

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]